TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26066525
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (70 mg for 16 weeks)
Study: 25274892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 synthetic disease-modifying antirheumatic drugs (sDMARD) and prednisolone (PRD), with infliximab or placebo infusions during the first 6 months
Study: 23239968
Drug: Inactivated subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated subunit influenza A (H7N7) vaccine 7.5 µg
Study: 23239968
Drug: Inactivated subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated subunit influenza A (H7N7) vaccine 15 µg
Study: 23239968
Drug: Inactivated subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated subunit influenza A (H7N7) vaccine 45 µg
Study: 23239968
Drug: Inactivated subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated subunit influenza A (H7N7) vaccine 90 µg
Study: 19882529
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium therapy (300 mg magnesium citrate for 1 month)
Study: 14705233
Drug: N of
Normalized name: Antigen of mold
Approvals — FDA: no, EMA: no, PMDA: no
Description: N of 1 trials with diclofenac 50 mg and misoprostol 200 microg twice a day for 2 weeks
Study: 14705233
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (stopping NSAID and waiting)
Study: 12085291
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) for plantar fasciitis
Study: 12085291
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) for lateral elbow epicondylitis (tennis elbow)
Study: 12085291
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) for calcifying tendinitis of the rotator cuff
Study: 23997361
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy (Thornton Adjustable Positioner type‐1, Airway Management, Inc., Dallas, TX, USA)
Study: 12935441
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA) 90 mg/m² every other day for 15 days
Study: 12935441
Drug: Oral ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ATRA (Vesanoid) 45 mg/m² daily for 15 days
Study: 12935441
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA)
Study: 12935441
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA) and Oral ATRA
Study: 10827385
Drug: Conventional pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pretreatment (heparin and aspirin)
Study: 31958293
Drug: Amoxicillin-metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-metronidazole
Study: 12781596
Drug: tolcapone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (two doses)
Study: 11187914
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment without asparaginase (ASP)
Study: 11187914
Drug: 24-hour daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-hour daunorubicin (DNR) infusion
Study: 11187914
Drug: 6-thioguanine (6-TG)
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine (6-TG) in maintenance treatment
Study: 11187914
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of systemic treatment
Study: 1283570
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 480 mg/day
Study: 1283570
Drug: Verapamil IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil IR (80 or 160 mg 3 times daily)
Study: 31004517
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet (ST‐OS)
Study: 31004517
Drug: Suspension in
Normalized name: SUSPENSION IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension in solid lipid nanoparticles (SLN-OS)
Study: 31004517
Drug: Transdermal jellified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal jellified melatonin microemulsion (μE-TD)
Study: 25112783
Drug: Fiber treatment
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber treatment (Plantago ovata husk)
Study: 22575433
Drug: Pictorial images
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pictorial images and electronic drug monitoring (EDM) review used in counseling
Study: 19602273
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (24 weeks)
Study: 24620666
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise therapy
Study: 8849215
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (50,000 U/kg/day in two divided doses for 10 days)
Study: 1627425
Drug: Neural-network-based artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural-network-based artificial intelligence for treatment decision-making
Study: 27748575
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care with tongue cleaning (intervention group; n = 58)
Study: 27748575
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care alone (control group; n = 56)
Study: 22048283
Drug: Oral Passiflora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Passiflora incarnata Linneaus extract
Study: 16003527
Drug: Ropinirole alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole alone or in combination with L-dopa
Study: 11826422
Drug: Amantadine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Study: 11826422
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Study: 11826422
Drug: Amantadine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a
Study: 10397536
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (20 mg pentavalent antimony per kg per day for 28 days)
Study: 10397536
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.7 mg/kg per day for 28 days)
Study: 6993035
Drug: Chemo-immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy with levamisole (2.5 mg/kg orally for 2 consecutive days each week while off chemotherapy)
Study: 6993035
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (standard regimen of cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 6993035
Drug: Chemo-immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy with levamisole
Study: 31430414
Drug: LINK (buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LINK (buprenorphine induction, in-patient dose stabilization and post-discharge transition to maintenance buprenorphine)
Study: 29458934
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with lavender oil for 5 sessions over 3 cycles
Study: 16646673
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) plus G-CSF
Study: 16646673
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) plus GM-CSF followed by G-CSF
Study: 10962675
Drug: Full strength
Normalized name: Dakins Full Strength Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full strength Burow's solution (13% aluminium acetate)
Study: 10962675
Drug: 3.25% aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.25% aluminium acetate solution (a quarter strength Burow's solution)
Study: 10962675
Drug: 1.3% aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3% aluminium acetate solution (1/10 strength Burow's solution)
Study: 27298569
Drug: Mirtazapine (MG)
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine (MG)
Study: 27298569
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CG)
Study: 25330631
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 2 years followed by 1 year follow-up and combined with 3-year drug therapy
Study: 25330631
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only drug therapy
Study: 18775608
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol
Study: 10771880
Drug: IPV (Inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV (Inactivated Polio Vaccine)
Study: 10771880
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of IPV starting from birth
Study: 10771880
Drug: IPV/OPV at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV/OPV at birth followed by 3 doses of OPV
Study: 10771880
Drug: Some vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some vaccine at birth (IPV or OPV)
Study: 10771880
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of IPV
Study: 8183102
Drug: Sodium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium concentration of 0 mmol.l‐1
Study: 8183102
Drug: Sodium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium concentration of 25 mmol.l‐1
Study: 8183102
Drug: Sodium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium concentration of 50 mmol.l‐1
Study: 3351300
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg (acute study)
Study: 3351300
Drug: Nisoldipine 25
Normalized name: nisoldipine 25.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 25 mg (chronic study)
Study: 25823403
Drug: NaOCl +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOCl + triple antibiotic paste (TAP) for 4 weeks followed by EDTA
Study: 25823403
Drug: NaOCl +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOCl + diluted triple antibiotic paste (DTAP) for 4 weeks followed by EDTA
Study: 23307511
Drug: Tα1 administration
Normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tα1 administration for 2 weeks
Study: 23307511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Tα1 administration)
Study: 23307511
Drug: Tα1 administration
Normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tα1 administration
Study: 11406837
Drug: Education package
Normalized name: zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Education package for the treatment of menorrhagia given to doctors at a primary care level
Study: 30470924
Drug: Immediate postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postpartum availability of the contraceptive implant
Study: 24057996
Drug: Topiramate/Nicotine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate/Nicotine patch (TOP/NIC)
Study: 2372267
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily + Aspirin 600 mg three times a day
Study: 20620742
Drug: High-flavanol intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol intervention (HiFI) [375 mg]
Study: 20620742
Drug: Low-flavanol intervention
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol intervention (LoFI) [9 mg]
Study: 9797692
Drug: Pamidronate 300
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 300 mg daily
Study: 2202024
Drug: Sprotte cannula
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprotte cannula (24 G)
Study: 2202024
Drug: Quincke cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quincke cannula (25 G)
Study: 64803
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg and 10 mg
Study: 64803
Drug: Prazosin 2
Normalized name: prazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 2 mg three times daily (rising to 5 mg if required)
Study: 64803
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (beta blockade, bendrofluazide, and prazosin)
Study: 24462960
Drug: 1.7% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7% hypertonic saline solution supplemented with 40 mg furosemide (salt infusion group)
Study: 24462960
Drug: Glucose supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose supplemented with 40 mg furosemide (glucose infusion group)
Study: 22955125
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (120 mg tablet, EGb‐761) twice a day for 12 weeks
Study: 22955125
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice a day for 12 weeks
Study: 20028712
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg twice a day
Study: 17684983
Drug: 10% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% albumin solution
Study: 16084882
Drug: G972A variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: G972A variant of insulin receptor substrate‐1 (IRS‐1) in women with PCOS
Study: 12601100
Drug: Pergolide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.15 to 0.45 mg per day)
Study: 10029283
Drug: Natural IFNalpha,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural IFNalpha, 10 MU, i.m. daily for 2 consecutive weeks and then three times per week for the subsequent 14 weeks (total dose 560 MU)
Study: 10029283
Drug: Natural IFNalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural IFNalpha treatment
Study: 6095655
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg as a single nighttime dose
Study: 31605515
Drug: HAL-based walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAL-based walking therapy
Study: 28393417
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg d1) in combination with granisetron and dexamethasone
Study: 28393417
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg d1; 80 mg d2-d3) in combination with granisetron and dexamethasone
Study: 25844619
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (45-g daily)
Study: 25844619
Drug: Isocaloric maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric maltodextrin supplement (control)
Study: 24517028
Drug: Paracetamol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1.0 g) co-administered with ferrous sulphate (300 mg)
Study: 24517028
Drug: Paracetamol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1.0 g) alone
Study: 12215864
Drug: Active gallium-arsenide
Normalized name: GALLIUM ARSENIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gallium-arsenide (Ga-As) laser therapy
Study: 12215864
Drug: Amitriptyline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline therapy (10 mg daily at bedtime for 8 weeks)
Study: 2782506
Drug: Other conditions
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other conditions designed to supplement the manual plus television
Study: 780001
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate aerosol, 800 mcg daily
Study: 29788815
Drug: Magnesium loading
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium loading dose (7.5 g of magnesium sulfate in 500 mL normal saline as intravenous infusion over an 8-hour period)
Study: 29788815
Drug: Magnesium loading
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium loading dose
Study: 25384603
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) group, 150 mg/kg IV bolus at anaesthetic induction followed by continuous infusion at 150 mg/kg per day for 24 hours.
Study: 11212970
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement (both active groups)
Study: 9609581
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline 5 mg every 6 hours for 24 hours
Study: 31421469
Drug: GP induction
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP induction chemotherapy
Study: 28645713
Drug: Q6 dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q6 dosing strategy (n=4)
Study: 28645713
Drug: Q8 dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q8 dosing strategy (n=6)
Study: 28645713
Drug: Q24 dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q24 dosing strategy (n=6)
Study: 15089817
Drug: Nifedipine controlled-release
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine controlled-release (CR) 20-40 mg daily
Study: 15089817
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20-40 mg daily
Study: 23705344
Drug: Multimodal Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal Music Therapy (MMT)
Study: 17845588
Drug: Xolair (omalizumab)
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xolair (omalizumab) treatment for 6 years followed by withdrawal
Study: 16329362
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential LASIK
Study: 9798529
Drug: ANP (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (7.5 ng/kg/min) infusion during high salt diet
Study: 9798529
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion during low salt diet
Study: 8566922
Drug: Graphite furnace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graphite furnace atomic absorption spectrophotometry (GFAAS) method for manganese determination
Study: 27524737
Drug: Transcutaneous interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transcutaneous interferential electrical stimulation plus behavioral therapy
Study: 29747432
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy alone
Study: 25794202
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of lidocaine 2%
Study: 25794202
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of lidocaine 2% + 1 mL of betametazone
Study: 20537740
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (n = 25)
Study: 15642569
Drug: Azimilide 75
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 75 mg
Study: 10642679
Drug: Erythromycin (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (divided doses for 14 days)
Study: 1337466
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimen 1
Study: 1337466
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimen 2
Study: 2423794
Drug: Indoramin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (75 mg/day for 2 weeks)
Study: 31691305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and RTW-I (COMBO)